There’s little doubt that vaccines are one of the most important medical advances ever created.  Between 2011 and 2020, vaccines will have averted over 23 million deaths in low-income countries. What’s more, according to the CDC, vaccines are responsible for saving the lives of…

Some 95 percent of cancer drugs launched around the globe are available in the U.S. Given that the U.S. is a global leader in ensuring patients have access to the newest therapies, the country has a profound impact on patient treatment and outcomes around the world. During the panel, Global…

Scientific advances in human genome editing have proven that somatic cell genome editing holds great potential to treat or maybe even cure genetic diseases. During the panel, Scientific Advances in Genome Editing: Where Are We Today?, panelists shared insights on how recent advances are…

Jamie Dimon, chairman and CEO of JPMorgan Chase & Co., headlined a keynote address this morning at the 2019 BIO International Convention. He chatted with Jim Greenwood, president and CEO of BIO, about what drives him, what he learned from fighting throat cancer and how he would fix some of our…

Placing patients at the center of everything the biotech industry stands for is a personal mission for Christi Shaw. In 1996, her mother, Karen, died of breast cancer. It was a tragic time for her and her two sisters. But tragedy would strike again as Christi’s sister, Sherry, was later diagnosed…

In a world of continual innovation in biopharmaceuticals, how do we ensure patients have access to the medicines that work to meet their individual needs? To discuss this important issue, we sat down with Merck Chief Patient Officer Dr. Julie Gerberding to discuss how we can better understand the…

Drug overdose deaths, including those involving opioids, reached 42,000 in 2016 (CDC), prompting a national response from the healthcare community to the sprawling crisis. The rise of opioid deaths appears to have occurred in three waves: first prescription opioids, followed by heroin, and most…

In the inaugural taping of Buzz at BIO, Jennifer Dent, who leads BIO Ventures for Global Health (BVGH), discusses the African Access Initiative, combatting the cancer crisis in Africa, BVGH’s role in giving African hospitals the ability to provide high-quality care, and her take on the 2019 BIO…

It’s obvious that cost presents a major burden for patient access to gene therapy. The recent approval of Novartis’ gene therapy Zolgensma, which treats children under two with spinal muscular atrophy (SMA), was quickly overshadowed by criticism about the drug’s $2.125 million price tag. As the…

Back in 1990, an experimental new treatment represented a bright light of hope for Ashanthi De Silva, who was just four at the time and became the first human to receive gene therapy. She was born with a crippled immune system due to inheriting two faulty copies of the gene responsible for…